TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03809858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Klue App
Description: The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Klue App
Description: The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
Study: NCT03663413

Intervention type: DEVICE
Intervention: non-invasive monitor
Description: cutaneous EEG monitor
Study: NCT02581137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study: NCT01239225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal ultra-sound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Study: NCT01125735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
Study: NCT02775123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
Study: NCT04750447

Intervention type: DEVICE
Intervention: XEN 63
Description: The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
Study: NCT00847847

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anconeus Muscle biopsy
Description: Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anconeus Muscle biopsy
Description: Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
Study: NCT02416973

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant
Study: NCT03752164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Mindfulness Skills
Description: Single brief session in which children are taught yoga and skills in mindfulness
Study: NCT03869411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised aerobic exercise or home-based aerobic exercise
Description: The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised aerobic exercise or home-based aerobic exercise
Description: The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised aerobic exercise or home-based aerobic exercise
Description: The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation.
Study: NCT00005843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study: NCT04193813

Intervention type: OTHER
Intervention: Observational
Description: Observational study

Intervention type: OTHER
Intervention: Observational
Description: Observational study
Study: NCT02121145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: 3 oral doses
Study: NCT02059031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Reference formulation
Description: GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 1
Description: GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 1
Description: GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 2
Description: GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
Study: NCT02121145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: 3 oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: 3 oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typherix
Description: one intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typherix
Description: one intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typherix
Description: one intramuscular dose
Study: NCT01459276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-6011
Description: One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with FluvalAB
Description: One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study: NCT01242488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 120 mg sc at Weeks 0, 2, 4 6, 8, and 10

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 240 mg sc at Weeks 0, 2, 4 6, 8, and 10

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab (Actemra or RoActemra)
Description: 8 mg/kg intravenously (iv) at Weeks 0, 4 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 60 mg sc at Weeks 0, 4 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 240 mg sc at Weeks 0, 4 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 120 mg sc at Weeks 0, 4 and 8
Study: NCT02059031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 2
Description: GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
Study: NCT01242488

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 2, 6 and 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 2, 6 and 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 2, 6 and 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8
Study: NCT04473729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual speech training in noise for children
Description: Children will participate in listening training in the form of an iPad app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual speech training in noise for children
Description: Children will participate in listening training in the form of an iPad app
Study: NCT01242488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8
Study: NCT02995668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength-Function
Description: Preoperative functional and strength capabilities training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength-Function
Description: Preoperative functional and strength capabilities training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance-Proprioception
Description: Preoperative proprioceptive and balance capabilities training
Study: NCT01518205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Description: The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used.
Study: NCT05029648

Intervention type: OTHER
Intervention: Cohort
Description: Cohort
Study: NCT05170698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaltion excision and arthroereisis
Description: Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coalition excision and corrective osteotomies
Description: Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
Study: NCT04121598

Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.

Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.

Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
Study: NCT04473729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual speech training in noise for children
Description: Children will participate in listening training in the form of an iPad app
Study: NCT00365469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available cow's milk based infant formula without probiotic supplementation
Study: NCT02269007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated quadrivalent influenza vaccine (split virion)
Description: 0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
Study: NCT01158976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexanoic Acid
Description: 450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soybean oils with strawberry flavoring
Study: NCT01461148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSP peptides
Description: 100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
Study: NCT02336698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study: NCT01513850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepabulin IV
Description: I.V.
Study: NCT01391377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin/Laropiprant combination
Description: Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo
Study: NCT02796326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: improved tracheal balloon dilatation
Description: Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
Study: NCT00723775

Intervention type: DRUG
Group type: OTHER
Intervention: GSK706769 & KALETRA
Description: GSK706769 alone and GSK706769 + Kaletra

Intervention type: DRUG
Group type: OTHER
Intervention: GSK706769 & KALETRA
Description: GSK706769 alone and GSK706769 + Kaletra
Study: NCT02973958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See experimental arm description
Study: NCT03210506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study: NCT05588518

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: desensitizing agents -10% Propolis
Description: 10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: desensitizing agents -10% Propolis
Description: 10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: desensitizing agents -10% Propolis
Description: 10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives.
Study: NCT02835534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase
Description: Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Study: NCT02073513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape plus thenar pressure (PPTG)
Description: In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taping Group (TG)
Description: In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
Study: NCT02336698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study: NCT03913364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: B. bifidum 900791-containing ice cream

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: B. bifidum 900791-containing ice cream

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ice-cream

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ice-cream
Study: NCT01116817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumbar puncture (Lopinavir/ritonavir monotherapy)
Description: Lumbar puncture at week 0